Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Non-Current Assets (2020 - 2026)

MoonLake Immunotherapeutics' Non-Current Assets history spans 7 years, with the latest figure at $3.7 million for Q1 2026.

  • Quarterly Non-Current Assets fell 25.31% to $3.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Mar 2026, down 25.31% year-over-year, with the annual reading at $2.7 million for FY2025, 24.84% down from the prior year.
  • Non-Current Assets came in at $3.7 million for Q1 2026, up from $2.7 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $115.1 million in Q1 2022 to a low of $52679.0 in Q3 2022.
  • The 5-year median for Non-Current Assets is $3.6 million (2024), against an average of $10.3 million.
  • Year-over-year, Non-Current Assets tumbled 99.95% in 2022 and then surged 3627.1% in 2023.
  • MoonLake Immunotherapeutics' Non-Current Assets stood at $331969.0 in 2022, then soared by 3627.1% to $12.4 million in 2023, then tumbled by 70.55% to $3.6 million in 2024, then dropped by 24.84% to $2.7 million in 2025, then skyrocketed by 36.29% to $3.7 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Non-Current Assets are $3.7 million (Q1 2026), $2.7 million (Q4 2025), and $3.1 million (Q3 2025).